Adverse events in the treatment of patients with pulmonary tuberculosis combined with diabetes mellitus and without it. Source: Virtual Congress 2021 – Tuberculosis, COVID-19 and other comorbidities Year: 2021
Comparison of the clinical manifestations of tuberculosis in patients with different type’s of diabetes mellitus and without it Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016
Clinical manifestations and efficacy MDR/XDR tuberculosis in patients with different type’s of diabetes mellitus Source: International Congress 2015 – Case series and clinical conundrums in TB Year: 2015
Risk of serious adverse reactions during the treatment of new tuberculosis patients Source: Annual Congress 2012 - Tuberculosis: clinical findings II Year: 2012
Factors associated with severity of pulmonary tuberculosis and mortality in TB patients with diabetes mellitus Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 1 Year: 2014
Frequency of side effects among patients with drug resistant tuberculosis (DR-TB) by resistance pattern in a high burden country. Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020
Effect of diabetes mellitus on the Time of mycobacterial clearance from sputum during the treatment of multi-drugs resistant tuberculosis Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 2 Year: 2014
Effectiveness of mesodiencephalic modulation in treatment of XDR TB patients with concomitant type II diabetes mellitus Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019
Diabetes mellitus as cause of treatment failure and relapses of pulmonary tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 311s Year: 2001
Spectrum of adverse drug reactions during MDR TB treatment Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Efficacy of treatment of MDR/XDR TB patients with diabetes mellitus Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Multi-drug resistant tuberculosis (MDR-TB) in Ramnicul Valcear, Romania; drug treatment, resistance testing and adverse drug reactions Source: Eur Respir J 2006; 28: Suppl. 50, 378s Year: 2006
Treatment patients with pulmonary tuberculosis (PT) and accompanying pathologies by DOTS strategy Source: Eur Respir J 2005; 26: Suppl. 49, 192s Year: 2005
Monitoring of antituberculous drugs adverse events during the treatment of multidrug-resistant pulmonary tuberculosis Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Influence of diabetes mellitus on sputum conversion rate in pulmonary tuberculosis and on antituberculous drug resistance Source: International Congress 2019 – Tuberculosis and comorbidities Year: 2019
Impact of diabetes mellitus on clinical parameters and treatment outcomes of diagnosed pulmonary tuberculosis patients Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1 Year: 2014
Mesodiencephalic modulation in the treatment of XDR TB patients with concomitant type II diabetes mellitus Source: Virtual Congress 2021 – Tuberculosis, COVID-19 and other comorbidities Year: 2021
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report Source: Eur Respir J, 54 (6) 1901522; 10.1183/13993003.01522-2019 Year: 2019
Surgical treatment of destructive pulmonary tuberculosis (TB) with multi-drug resistance (MDR) Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004
Treatment results in patients with drug resistant pulmonary tuberculosis Source: Eur Respir J 2002; 20: Suppl. 38, 612s Year: 2002